US Regulators Considering Moving Forward With Johnson & Johnson Vaccine

Johnson & Johnson’s COVID-19 vaccine was paused last week and is now officially under review in the United States.

For the record, European nations have kept the vaccine, with the warning that it comes with a “very low risk” of blood clots. The U.S. apparently is thinking of moving ahead with J&J in the same manner.

“New guidance is expected late Friday after a government advisory panel deliberates a possible link between J&J’s shot and a handful of vaccine recipients who developed highly unusual blood clots,” The Associated Press reported.

As it stands, the Centers for Disease Control and Prevention has turned to advisers to determine how big the risk of clotting actually is. Unlike the Pfizer and Moderna double-dose vaccinations, J&J is limited to just one shot.

Per The AP: “At issue is a weird kind of blood clot that forms in unusual places, such as veins that drain blood from the brain, and in patients with abnormally low levels of the platelets that form clots. The CDC and Food and Drug Administration initially spotted six people who developed such clots one to three weeks after J&J vaccination, including one death. “

Written by Sam Amico

Sam Amico spent 15 years covering the NBA for Sports Illustrated, FOX Sports and NBA.com, along with a few other spots, and currently runs his own basketball website on the side, FortyEightMinutes.com.

5 Comments

Leave a Reply

Leave a Reply